Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 285, Issue 1 29-1, 2003, Pages

  Prabhakaran, Priya ^b   Ware, Lorraine B ^d   White, Kimberly E ^c   Cross, Michael T ^a   Matthay, Michael A ^e   Olman, Mitchell A ^a,c,f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

Fibrinolysis; Prognosis

Indexed keywords

D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACUTE DISEASE; ADULT; AGED; ARTICLE; ASSISTED VENTILATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FIBRINOLYSIS; HUMAN; HYDROSTATIC PRESSURE; LUNG EDEMA; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

EID: 0038805215     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00312.2002     Document Type: Article

References (50)

1. Barazzone C, Belin D, Piguet PF, Vassalli JD, and Sappino AP. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 98: 2666-2673, 1996.
2. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Le Gall JR, Morris A, and Spragg R. The American-European consensus conference on ARDS. Am J Respir Crit Care Med 149: 818-824, 1994.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, and Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709, 2001.
4. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, and Chapman HA. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 322: 890-897, 1990.
5. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9: 714-724, 1997.
6. Chapman HA, Yang X, Sailor LZ, and Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. J Immunol 145: 3398-3405, 1990.
7. Chesnutt AN, Matthay MA, Tibayan FA, and Clark JG. Early detection of type III procollagen peptide in acute lung injury. Am J Respir Crit Care Med 156: 840-845, 1997.
8. Clark JG, Milberg JA, Steinberg KP, and Hudson LD. Type III procollagen peptide in the adult respiratory distress syndrome. Ann Intern Med 122: 17-23, 1995.
9. Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, and Matthay MA. Identification of patients with acute lung injury: predictors of mortality. Am J Respir Crit Care Med 152: 1818-1824, 1995.
10. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, and Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1: 232-237, 1996.
11. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Vergilio J, and Nicholson AC. Macrophage and foam cell release of matrix-bound growth factors. J Biol Chem 268: 11951-11958, 1993.
12. Fan J, Kapus A, Li YH, Rizoli S, Marshall JC, and Rotstein OD. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: a role of tumor necrosis factor. Am J Respir Crit Care Med 22: 412-421, 2000.
13. Francis CW, Marder VJ, and Barlow GH. Plasmic degradation of crosslinked fibrin. J Clin Invest 66: 1033-1043, 1980.
14. Fuchs-Buder T, deMoerloose P, Ricou B, Reber G, Vifian C, Nicod L, Romand JA, and Suter PM. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 153: 163-167, 1996.
15. Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL, Walz A, Hudson LD, and Martin TR. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 154: 602-611, 1996.
16. Gunther A, Kalinowski M, Rosseau S, and Seeger W. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. Am J Respir Cell Mol Biol 13: 712-718, 1995.
17. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, and Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Am J Respir Crit Care Med 161: 454-462, 2000.
18. Hagood JS, Olman MA, Zeballos JG, Rivera KE, and Fuller GM. Regulation of type I plasminogen activator inhibitor by fibrin degradation products in rat lung fibroblasts. Blood 87: 3749-3757, 1996.
19. Hattori N, Degen J, Sisson T, Lui H, Moore B, Pandrangi R, Simon R, and Drew A. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 106: 1441-1443, 2000.
20. Horton MR, Olman MA, Bao C, Rivera KE, Choi AMK, Chin BY, Noble PW, and Lowenstein CJ. Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages. Am J Physiol Lung Cell Mol Physiol 279: L207-L215, 2000.
21. Idell S. Anticoagulants for acute respiratory distress syndrome. Can they work? Am J Respir Crit Care Med 164: 517-520, 2001.
22. Idell S. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med 30: S274-S280, 2002.
23. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, and Fair DS. Local abnormalities in coagulation and fibrinolytic pathways predisposed to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 84: 695-705, 1989.
24. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, and Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 261: L240-L248, 1991.
25. Idell S, Mazar AP, Bitterman P, Mohla S, and Harabun AL. Fibrin turnover in lung inflammation and neoplasia. An NHLBI/NCI workshop. Am J Respir Crit Care Med 163: 578-584, 2001.
26. Idell S, Zwieb C, Boggaram J, Holiday D, and Johnson AR. Mechanisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-β and TNF-α. Am J Physiol Lung Cell Mol Physiol 263: L487-L494, 1992.
27. Lang IM, Marsh JJ, Olman MA, Moser KM, and Schleef RR. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 90: 706-712, 1994.
28. Le Gall JR, Lemenshow S, and Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957-2963, 1993.
29. Milberg JA, Davis DR, Steinberg KP, and Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 273: 306-309, 1995.
30. Monchi M, Bellenfant F, Cariou A, Joly L, Thebert D, Laurent I, Dhainaut JF, and Brunet F. Early predictive factors of survival in the acute respiratory distress syndrome. Am J Respir Crit Care Med 158: 1076-1081, 1998.
31. Olman M, Mackman N, Gladson C, Moser K, and Loskutoff D. Changes in procoagulant and fibrinolytic gene expression during bleomycin induced lung injury in the mouse. J Clin Invest 96: 1621-1630, 1995.
32. Olman MA, Hagood JS, Simmons WL, Fuller GM, Vinson C, and Rivera KE. Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element. Blood 94: 2029-2038, 1999.
33. Olman MA, Marsh JJ, Lang IM, Moser KM, Binder BR, and Schleef RR. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 86: 1241-1248, 1992.
34. Olman MA, Simmons WL, Pollman DJ, Loftis AY, Bini A, Miller EJ, Fuller GM, and Rivera K. Polymerization of fibrinogen in murine bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol 271: L519-L526, 1996.
35. Pittet JF, Griffiths MJD, Geiser T, Kaminski N, Dalton SL, Huang X, Brown LAS, Gotwals PJ, Koteliansky VE, Matthay MA, and Sheppard D. TGF-β is a critical mediator of acute lung injury. J Clin Invest 107: 1537-1544, 2001.
36. Pittet JF, Mackersie RC, Martin TR, and Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 155: 1187-1205, 1997.
37. Pugin J, Ricou B, Steinberg KP, Suter PM, and Martin TR. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med 153: 1850-1856, 1996.
38. Schoenfeld DA and Bernard GR. Evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 30: 1772-1777, 2002.
39. Seeger W, Grube C, and Gunther A. Proteolytic cleavage of fibrinogen: amplification of its surfactant inhibitory capacity. Am J Respir Cell Mol Biol 9: 239-247, 1993.
40. Sisson T, Hattori N, Xu Y, and Simon R. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 10: 2315-2323, 1999.
41. Sitrin RG, Pan PM, Harper HA, Blackwood RA, and Todd RF. Urokinase receptor (CD87) aggregation triggers phosphoinositide hydrolysis and intracellular calcium mobilization in mononuclear phagocytes. J Immunol 163: 6193-6200, 1999.
42. Suffrendini AF, Harpel PC, and Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320: 1165-1172, 1989.
43. The Acute Respiratory Distress Network. Ventilation with lower tidal volumes compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301-1308, 2000.
44. Verghese GM, McCormick-Shannon K, Mason RJ, and Matthay MA. Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Am J Respir Crit Care Med 158: 386-394, 1998.
45. Verghese GM, Ware LB, Matthay BA, and Matthay MA. Alveolar epithelial fluid transport and the resolution of clinically severe hydrostatic pulmonary edema. J Appl Physiol 87: 1301-1312, 1999.
46. Ware LB and Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 163: 1376-1383, 2001.
47. Ware LB and Matthay MA. Medical progress: the acute respiratory distress syndrome. N Engl J Med 342: 1334-1349, 2000.
48. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, and Chapman HA. Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996.
49. Zar JH. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, 1984.
50. Zilberberg MD and Epstein SK. Acute lung injury in the medical ICU. Am J Respir Crit Care Med 157: 1159-1164, 1998.